Radium-223

Tellbio’s Technology Demonstrates that Analysis of Circulating Tumor Cells Can Predict Survival Among Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Radium-2230

Retrieved on: 
Wednesday, March 27, 2024
OS, Harvard Medical School, DOI, Radium-223, Prostate cancer, Gene expression, Metastasis, Doctor of Pharmacy, JCO, Assistant, Patient, Tap, Biomarker, RNA, Chinese, Quality of life, CRPC, Senior, Hospital, Prognosis, CTC, Radiation therapy, PSA, FDA, CTCM, Medical imaging

ANDOVER, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- TellBio, Inc., a development-stage medical technology company focused on revolutionizing the detection of cancer metastasis through its unique and proprietary circulating tumor cell (CTC) technology, the TellDx CTC System, announces the publication of data that shows the promise of CTCs as a prognostic biomarker for patients with prostate cancer receiving novel therapies such as radium-223. The paper, “Circulating and Imaging Biomarkers of Radium-223 Response in Metastatic Castration-Resistant Prostate Cancer,” was published in JCO Precision Oncology (DOI 10.1200/PO.23.00230).

Key Points: 
  • The paper, “Circulating and Imaging Biomarkers of Radium-223 Response in Metastatic Castration-Resistant Prostate Cancer,” was published in JCO Precision Oncology (DOI 10.1200/PO.23.00230 ).
  • “Radium-223 is a valuable treatment option for patients with mCRPC, but better biomarkers are needed to identify patients most likely to benefit from therapy.
  • Additionally, imaging assessment in patients with bone-predominant disease has also been limited in patients receiving radium-223.
  • Upon controlling for known prognostic markers, PSA and tAP, the presence of baseline CTC AR-V7 expression was most predictive of OS among patients receiving radium-223.

Oncoinvent Announces Changes to its Board of Directors and Formation of Scientific and Clinical Advisory Board

Retrieved on: 
Tuesday, April 2, 2024
Oncology, Health, Clinical Trials, Radiology, Pharmaceutical, Biotechnology, MSD, Ovarian cancer, Mirati Therapeutics, London Business School, University of Coimbra, GSK, BMS, Doctor of Philosophy, Therapy, Algeta, Colorectal cancer, International, Pharmacy, Radiopharmaceutical, Radium-223, Agios Pharmaceuticals, Amgen, Cubist Pharmaceuticals, Takeda Pharmaceutical Company, Bristol Myers Squibb, University, Private sector, The central science, Drug development, Sanofi, Psychiatry, BASF, Master of Science, M.B.A, Science, GE HealthCare, Pharmaceutical industry

“We are excited to welcome an internationally renowned group of industry leaders as new members of our Board of Directors.

Key Points: 
  • “We are excited to welcome an internationally renowned group of industry leaders as new members of our Board of Directors.
  • “We are also pleased to announce the formation of a Scientific and Clinical Advisory Board, consisting of our highly distinguished founders who are uniquely positioned to support Oncoinvent in our clinical programs.
  • Dr. O’Bryan-Tear has been an adviser to several US and European biotech companies and has held board positions at Fusion Pharmaceuticals and Clarity Pharmaceuticals.
  • In addition, Oncoinvent founding scientists Roy Larsen, Ph.D., and Øyvind Bruland, M.D., Ph.D., previously board members, will lead a newly established Scientific and Clinical Advisory Board.

Bayer Unveils Latest Data from Oncology Portfolio at ESMO Congress 2023

Retrieved on: 
Thursday, October 12, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Congress, Disease, Trifluridine/tipiracil, Hepatocellular carcinoma, NSCLC, PLT, ORR, Bevacizumab, Observational study, Liver transplantation, Safety, Lung cancer, Mutation, RAS, Metastasis, Cancer, NTRK, European Society for Medical Oncology, ESMO, FDA, Prostate-specific antigen, Docetaxel, Quality of life (healthcare), Radium, Phase, REG, BAY, ADT, Patient, PSA, CNS, HCC, TRK, Radium-223, TKI, Pharmaceutical industry, Bayer

Bayer will present new data from across its oncology portfolio at the upcoming European Society for Medical Oncology (ESMO) Congress taking place in Madrid, Spain from October 20-24, 2023.

Key Points: 
  • Bayer will present new data from across its oncology portfolio at the upcoming European Society for Medical Oncology (ESMO) Congress taking place in Madrid, Spain from October 20-24, 2023.
  • The breadth of new data showcases Bayer’s ongoing commitment to supporting patients living with cancer.
  • In addition, Bayer will present new data on health-related quality of life (HRQoL) deterioration-free survival (DetFS) by PSA decline in the Phase III ARAMIS trial in patients with non-metastatic castration-resistant prostate cancer (nmCRPC).
  • Details on presentations from Bayer for the 2023 ESMO Congress are listed below:
    Regorafenib (REG) in patients (pts) with unresectable hepatocellular carcinoma (uHCC) in real-world (RW) practice: Final analysis of the prospective, observational REFINE study by prior liver transplantation (PLT)

Bayer Presents New Data Across Oncology Portfolio at the 2023 ASCO Annual Meeting

Retrieved on: 
Thursday, May 25, 2023
Pharmaceutical, Health, Oncology, Docetaxel, Thyroid, Observational study, Mutation, ADT, Radium, Science, ASCO, DEAR, American Society of Clinical Oncology, Metastasis, Patient, NTRK, Annual general meeting, Disease, Copanlisib, RWE, Radium-223, FDA, Aryl hydrocarbon receptor, Safety, Society, ORR, TC, Enza, TRK, Medical imaging, Pharmaceutical industry, Daro District, Bayer

Bayer will highlight scientific research in oncology at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting , taking place from June 2-6, 2023.

Key Points: 
  • Bayer will highlight scientific research in oncology at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting , taking place from June 2-6, 2023.
  • These presentations continue to underscore the company’s commitment to drive treatment approaches through science and innovation in the oncology space.
  • Data featuring NUBEQA® (darolutamide) and Xofigo® (radium Ra 223 dichloride) will be showcased at ASCO.
  • NUBEQA data includes results from the DEAR trial, a retrospective, observational study evaluating real-world evidence (RWE) in patients with non-metastatic castration-resistant prostate cancer (nmCRPC).

Bayer Demonstrates Commitment to Advancing Oncology by Showcasing New Data From Innovative Science at ESMO Congress 2022

Retrieved on: 
Tuesday, August 30, 2022
Oncology, Health, Clinical Trials, Research, Pharmaceutical, Science, COVID-19, Fatigue, Safety, Pain, Ari, Food and Drug Administration, Bleeding, Precision medicine, Toxicity, ESMO, Cardiac arrest, Myocardial infarction, Birth, Congress, Urinary retention, ADT, TRK, ORR, Pulmonary embolism, DASL, Adult, Moyamoya disease, Risk, Prostate cancer, Sudden death, ESCC, Patient, Bone, Female, Dyslipidemia, Hypocalcemia, Seizure, Appetite, Death, Heart failure, Food, MCRPC, FDA, Hematuria, Diabetes, Data, Docetaxel, Hyperglycemia, Consciousness, Disease, Cancer, Pneumonia, AST, Recurrence, Fatal, Rash, Radium, Quality of life, Lists of diseases, Constipation, Immunotherapy, Febrile neutropenia, ALP, Mutation, Heart, Anemia, Bilirubin, Nivolumab, ALT, Orion Corporation, Hypertension, Pregnancy, Pharmaceutical industry, Medical imaging, EU, Bayer, ARAMIS, Radium-223

Bayer will present key scientific research in oncology at the upcoming ESMO Congress 2022 from September 9-13, 2022.

Key Points: 
  • Bayer will present key scientific research in oncology at the upcoming ESMO Congress 2022 from September 9-13, 2022.
  • Bayer is committed to delivering science for a better life by advancing a portfolio of innovative treatments.
  • The oncology franchise at Bayer includes six marketed products and several other assets in various stages of clinical development.
  • Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition.

BWXT Medical and Bayer AG Enter into Agreement for the Development and Production of Actinium-225

Retrieved on: 
Thursday, September 16, 2021
Biotechnology, Health, Stem Cells, Pharmaceutical, Oncology, People, Risk, U.S. Securities and Exchange Commission, Automation, Security (finance), Taipei, Radiopharmaceutical, TAT, Form 10-K, Prostate cancer, Nuclear medicine, United States Department of Energy, BWX Technologies, PSMA, Annual report, NYSE, Neoplasm, BWXT, Tat, Radium-223, NASA, Twitter, Radiation, Cancer, Actinium-225, Pharmaceutical industry, Medical imaging

BWXT Medical is a global supplier of medical isotopes and radiopharmaceuticals.

Key Points: 
  • BWXT Medical is a global supplier of medical isotopes and radiopharmaceuticals.
  • Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition.
  • BWXT Medical plans to utilize its deep relationships with strategic partners in irradiation services and development of Ac-225.
  • Much like BWXT Medicals other products, processing and manufacturing would then be conducted at BWXT Medical facilities.

Bayer to Present Data that Reinforce Established Prostate Cancer Portfolio at 2021 ASCO GU Cancers Symposium

Retrieved on: 
Monday, February 8, 2021
Health, Science, Research, Clinical trials, Oncology, Anatomy, Chemistry, Organ systems, Nitriles, Nonsteroidal antiandrogens, Chloroarenes, Pyrazoles, Antiprogestogens, Darolutamide, Prostate cancer, Radium-223, Prostate, NUBEQA® (darolutamide)2, Xofigo® (radium Ra 223 dichloride) Injection3, Prostate Cancer, Oncology at Bayer, Bayer

Bayer announced today that new NUBEQA (darolutamide) and Xofigo (radium Ra 223 dichloride) data will be presented at the 2021 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium , taking place from February 11-13, 2021.

Key Points: 
  • Bayer announced today that new NUBEQA (darolutamide) and Xofigo (radium Ra 223 dichloride) data will be presented at the 2021 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium , taking place from February 11-13, 2021.
  • Our priority at Bayer is to advance the treatment of men with prostate cancer across the disease continuum.
  • The focus of our data at ASCO GU 2021 is reflective of our patient-centric approach to prostate cancer research, said Scott Z.
  • NUBEQA (darolutamide) is an androgen receptor inhibitor indicated for the treatment of patients with non-metastatic castration-resistant prostate cancer.

Analysis Group Team Publishes Real-World Evidence in Sequencing of Radium-223 Radiotherapy for Patients with Metastatic Castration Resistant Prostate Cancer

Retrieved on: 
Thursday, October 22, 2020
Anatomy, Organ systems, Physical sciences, RTT, Histopathology, Prostate cancer, MCRPC, Radium-223, Prostate, Radium, Management of prostate cancer, Prostvac

The retrospective analysis, published in the Naturejournal Prostate Cancer and Prostatic Diseases , focuses on the question of whether radium-223 should be administered before or after patients receive chemotherapy.

Key Points: 
  • The retrospective analysis, published in the Naturejournal Prostate Cancer and Prostatic Diseases , focuses on the question of whether radium-223 should be administered before or after patients receive chemotherapy.
  • This approach has led to widely varying patterns in the contemporary use of radium-223 amid a growing number of treatment options for patients with mCRPC.
  • "This was a non-interventional, retrospective, longitudinal chart review study of patients at the Dana-Farber Cancer Institute in Boston," said Dr. Duh.
  • The study, "Treatment of Metastatic Castration Resistant Prostate Cancer with Radium-223: A Retrospective Study at a US Tertiary Oncology Center," was published in the August 2020 issue of Prostate Cancer and Prostatic Diseases.

 Bayer to Showcase New Data from Evolving Oncology Portfolio at ESMO Virtual Congress 2020

Retrieved on: 
Tuesday, September 8, 2020
Research, Clinical trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Oncology, Organic compounds, Chemical compounds, Chemistry, Aspirin, Bayer, IG Farben, Leverkusen, Orphan drugs, ESMO, Radium-223, Sorafenib, VITRAKVI® (larotrectinib), NUBEQA, Stivarga® (regorafenib), NEXAVAR® (sorafenib) Tablets4, Xofigo® (radium Ra 223 dichloride) Injection, Oncology at Bayer, Bayer

Data from Bayers evolving oncology portfolio will be presented at the ESMO Virtual Congress 2020, taking place September 19-21, 2020.

Key Points: 
  • Data from Bayers evolving oncology portfolio will be presented at the ESMO Virtual Congress 2020, taking place September 19-21, 2020.
  • Notable presentations at the ESMO Virtual Congress 2020 are listed below.
  • The oncology franchise at Bayer includes six marketed products across various indications and several compounds in different stages of clinical development.
  • BAYER, the Bayer Cross, Vitrakvi, Nubeqa, Stivarga, Nexavar, and Xofigo are registered trademarks of Bayer.

Bayer to Present Data from Growing Oncology Portfolio at the ASCO20 Virtual Scientific Program

Retrieved on: 
Monday, May 11, 2020
Biotechnology, Pharmaceutical, Health, Oncology, Companies, Health, Aspirin, Bayer, IG Farben, Leverkusen, American Society of Clinical Oncology, Industries, Radium-223, Asco, NUBEQA, VITRAKVI® (larotrectinib), Xofigo® (radium Ra 223 dichloride) Injection, Stivarga® (regorafenib), Aliqopa TM (copanlisib) Injection5, Oncology at Bayer, Bayer

Data from Bayers growing oncology portfolio will be presented at the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program, taking place from May 29-31, 2020.

Key Points: 
  • Data from Bayers growing oncology portfolio will be presented at the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program, taking place from May 29-31, 2020.
  • Information on the registration as well as the virtual scientific program can be found here .
  • The oncology franchise at Bayer now expands to six marketed products and several other assets in various stages of clinical development.
  • BAYER, the Bayer Cross, Vitrakvi, Nubeqa, Xofigo, Stivarga, and Aliqopa are registered trademarks of Bayer.